SCHEMBL204290

SCHEMBL204290

CC(C)(C)OC(=O)NCCn1c(=S)[nH]c2cnc3cccnc3c21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.42
KDM4E B2RXH2 3/20 0.41
TDP1 Q9NUW8 1/20 0.41
ALDH1A1 P00352 1/20 0.40
GFER P55789 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
DRD2 P14416 2/20 0.37
LMNA P02545 1/20 0.37
LATS1 O95835 2/20 0.36
CYP3A4 P08684 2/20 0.36
STING1 Q86WV6 3/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
DYRK1A Q13627 1/20 0.35
JAK2 O60674 1/20 0.35
JAK1 P23458 1/20 0.35
PDPK1 O15530 1/20 0.35
CCNB2 O95067 1/20 0.35
PRKCB P05771 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL202257 0.85 MPO (0.34) KDM4E
SCHEMBL202268 0.77 KDM4E (0.41) BCHEKDM4ETDP1L3MBTL1DRD2
SCHEMBL202649 0.77 KDM4E (0.41) BCHEKDM4ETDP1L3MBTL1DRD2
SCHEMBL12888449 0.77 KDM4E (0.44) BCHEKDM4ETDP1ALDH1A1L3MBTL1
SCHEMBL4156877 0.77 KDM4E (0.44) BCHEKDM4ETDP1L3MBTL1DRD2
SCHEMBL3353897 0.75 TLR7 (0.47) KDM4ETDP1ALDH1A1L3MBTL1LMNA
SCHEMBL4147523 0.75 GAA (0.43) KDM4ETDP1L3MBTL1DRD2CYP3A4
Butane SCHEMBL6297560 0.75 KDM4E (0.42) BCHEKDM4ETDP1L3MBTL1DRD2
SCHEMBL202089 0.75 DYRK1A (0.44) BCHEALDH1A1GFERDRD2DYRK1A
SCHEMBL1231989 0.74 KDM4E (0.45) BCHEKDM4ETDP1L3MBTL1DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088788-B2 Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-01-03 US disclosed
US-20090221551-A1 SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS PFIZER INC. 2009-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221551-A1 SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS IL2, IFNG, IL4 BCHE 4218/4885KDM4E 2419/4885TDP1 4146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.